Pharmacokinetic evaluation of piperacillin-tazobactam

被引:69
|
作者
Hayashi, Yoshiro [2 ]
Roberts, Jason A. [1 ,3 ,4 ]
Paterson, David L. [2 ,5 ]
Lipman, Jeffrey [1 ,3 ]
机构
[1] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Dept Infect Dis, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
beta-lactamases; pharmacodynamics; pharmacokinetics; piperacillin-tazobactam; Pseudomonas aeruginosa; INFECTIOUS-DISEASES-SOCIETY; CRITICALLY-ILL PATIENTS; IN-VITRO ACTIVITY; CONTINUOUS VENOVENOUS HEMOFILTRATION; SINGLE-DOSE PHARMACOKINETICS; BETA-LACTAM ANTIBIOTICS; INTENSIVE-CARE-UNIT; DOUBLE-BLIND; CONTINUOUS-INFUSION; ANTIMICROBIAL SUSCEPTIBILITY;
D O I
10.1517/17425255.2010.506187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Importance of the field: Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. However, its pharmacokinetics (PK) can be significantly altered in a variety of states. Areas covered in this review: This article provides a comprehensive and critical review of the PK of piperacillin-tazobactam in different patient populations. The pharmacodynamics (PD) of piperacillin-tazobactam is also discussed. What the reader will gain: The importance of appropriate antibiotic dosing in the context of the global tendency for reduced susceptibility of bacteria, including P. aeruginosa is emphasized. The interrelationship between PK and PD is discussed to provide an understanding of methods for procuring dosing regimens that increase the likelihood of clinical success for individual patients. Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described. Take home message: Where piperacillin-tazobactam is required for treatment, applying knowledge of PK and PD characteristics can facilitate optimal outcomes.
引用
收藏
页码:1017 / 1031
页数:15
相关论文
共 50 条
  • [31] Reply to "Delayed hypersensitivity reactions to piperacillin-tazobactam"
    Gallardo, Alicia
    Moreno, Esther M.
    Laffond, Elena
    Munoz-Bellido, Francisco J.
    Teresa Gracia-Bara, M.
    Macias, Eva M.
    Valle Campanon, M.
    de Arriba, Sonia
    Martin, Cristina
    Sobrino, Miriam
    Davila, Ignacio
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2549 - 2549
  • [32] HYPERSENSITIVITY MYOCARDITIS ASSOCIATED WITH PIPERACILLIN-TAZOBACTAM USE
    Jafri, Firas
    Arif, Shahrukh
    Ashraf, Uzair
    CHEST, 2020, 158 (04) : 226A - 226A
  • [33] PIPERACILLIN-TAZOBACTAM TREATMENT FOR SEVERE INTRAABDOMINAL INFECTIONS
    LEGRAND, JC
    BASTIN, F
    BELVA, P
    CHASTEL, C
    RENAUX, J
    VANEUKEM, P
    ACTA CHIRURGICA BELGICA, 1995, 95 (03) : 162 - 165
  • [34] Piperacillin-Tazobactam Hypersensitivity: A Large, Multicenter Analysis
    Casimir-Brown, Rosamund Sara
    Kennard, Lucinda
    Kayode, Oyindamola Stephanie
    Siew, Leonard Q. C.
    Makris, Michael
    Tsilochristou, Olympia
    Chytiroglou, Evangelia
    Nakonechna, Alla
    Rutkowski, Krzysztof
    Mirakian, Rita
    Wagner, Annette
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (05): : 2001 - 2009
  • [35] Piperacillin-tazobactam:: a β-lactam/β-lactamase inhibitor combination
    Gin, Alfred
    Dilay, Leanne
    Karlowsky, James A.
    Walkty, Andrew
    Rubinstein, Ethan
    Zhanel, George G.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (03) : 365 - 383
  • [36] ANTISTAPHYLOCOCCAL EFFICACY OF CEFEPIME, PIPERACILLIN-TAZOBACTAM, AND MEROPENEM
    Subedi, Bibidh
    Najia, Laila
    Pyles, Eric
    Ruiz, Arnaldo Lopez
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 337 - 337
  • [37] Assessment of biliary excretion of piperacillin-tazobactam in humans
    Westphal, JF
    Brogard, JM
    CaroSampara, F
    Adloff, M
    Blickle, JF
    Monteil, H
    Jehl, F
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1636 - 1640
  • [38] The use of piperacillin-tazobactam in neonatal and paediatric patients
    Wolf, Maria F.
    Simon, Arne
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (01) : 57 - 69
  • [39] Quantitative pharmacokinetic patients relationship (QPPR) for piperacillin-tazobactam during continuous venovenous heamodialysis/filtration
    Saxena, Aaruni
    Tyagi, Kapil
    Muller, Silke C.
    Drewelow, Bernd
    MEDICINAL CHEMISTRY RESEARCH, 2008, 17 (2-7) : 199 - 204
  • [40] Evaluation of Piperacillin-Tazobactam for Antibiotic Prophylaxis in Traumatic Grade III Open Fractures
    O'Connell, Casey R.
    Kooda, Kirstin J.
    Sawyer, Mark D.
    Wise, Kevin B.
    Mara, Kristin C.
    Skrupky, Lee P.
    SURGICAL INFECTIONS, 2022, 23 (01) : 41 - 46